Close Menu
    What's Hot

    Competitive Pension Risk Transfer Cost Climbs to in March

    30 April 2025

    The College of Law Pension and Assurance Scheme Completes Buy-In with Royal London

    29 April 2025

    The Gleaner Pension Scheme Secures Full Scheme Buy-Out With Aviva

    29 April 2025
    Facebook X (Twitter) Instagram
    Instagram LinkedIn X (Twitter)
    Life Risk News
    • Home
    • Features

      Life Insurer Credit Risk in the News Again but Life Settlement Market Keeps On Keeping On

      10 April 2025

      Capital-Backed Journey Plans Re-Enter Defined Benefit Pension De-Risking Debate as New Rules Loom

      10 April 2025

      Understanding the Impact of Covid-19 on Future Mortality Remains an Almost Impossible Task

      10 April 2025

      Canadian Pension Risk Transfer Market Set To Establish Higher Floor as Aggregate Deal Value Surges

      10 April 2025

      Q&A: Martin Kramer, Managing Partner, Ceptar Consulting

      10 April 2025
    • Commentary

      Could Climate Change Cause the Buy-In Market To Collapse?

      10 April 2025

      ICS vs Solvency II: Comparing Risk Corrections for Illiquid Liabilities

      10 April 2025

      Falls: Significance in Life Expectancy Underwriting

      13 March 2025

      Spotlight on Longevity Capital Models

      13 March 2025

      Bulk Annuities: Who Steers the Ship?

      12 February 2025
    • Events
    • Magazine
    • News

      Competitive Pension Risk Transfer Cost Climbs to in March

      30 April 2025

      The College of Law Pension and Assurance Scheme Completes Buy-In with Royal London

      29 April 2025

      The Gleaner Pension Scheme Secures Full Scheme Buy-Out With Aviva

      29 April 2025

      ELG Haniel Metals Limited Pension and Assurance Scheme Completes Buy-In with Just Group

      24 April 2025

      Hudson Structured Capital Management Promotes Sudarsana to Partner

      14 April 2025
    Subscribe
    Life Risk News
    Home » Deciphering Longevity Assessment: Unveiling Macro-Longevity and Micro-Longevity Perspectives

    Deciphering Longevity Assessment: Unveiling Macro-Longevity and Micro-Longevity Perspectives

    Commentary 11 October 2023Christopher ConwayBy Christopher Conway
    Twitter LinkedIn Email
    Share
    Twitter LinkedIn Email

    In an effort to differentiate between cohort and large population mortality information that predominates most discussions about longevity, life expectancy and other life underwriting-related topics, we have used two different terms. We use the term macro-longevity to refer to information about life expectancy involving large groups of people, the population of the United States for example. We use the term micro-longevity when we talk about the life expectancy (LE) of an individual. However, these are merely labels we use to keep any discussion about longevity risk focused on the situation at hand. 

    Using These Terms and Their Scope 

    We do not use the terms macro-longevity (risk) and micro-longevity (risk) to describe or imply anything about our underwriting methodology or the data and information we use to develop our underwriting tools or conduct our life expectancy assessments. The information we use to inform our underwriting philosophy, develop our underwriting manual, and apply our underwriting methodology is vast and constantly growing. As we assess more and more lives over time, this body of work expands and we learn more and more about the macro and micro implications of our work. In addition, we often see the work product of our competitors and we are occasionally asked to explain our assessment relative to that of one or more competitors who have evaluated the same individual. However, we are never asked to explain our assessment when the mean life expectancy figure assigned to the insured as a result of our underwriting is shorter than that of a competitor. Only when our LE is longer are we questioned. (We assume our competitors get these questions too when their LEs are longer than ours or any other underwriting firm). 

    Comparing Competitor Assessments 

    The question we are most often asked is, simply put, “Why is your LE longer than this other underwriter’s?” Usually, when the question is first posed, we have no documentation or any information about what the other underwriting firm’s report says. We always ask for this information, because without it, we cannot compare and contrast our work product with anything other than the assertion that our LE is longer than someone else’s LE. Once we have both sides of the picture, we do the work of comparing our assessment with that of our competitor(s). 

    The first thing we look for is the mortality rating applied to the insured by our competitor and the rating we applied. If they are the same (and it’s becoming increasingly rare that they are), and the LEs are different, we know that this is likely to be caused by a difference in the morality table used to calculate the LE figures themselves. In other words, if a given insured person is viewed by ISC and another underwriting firm as being impaired to the same degree (eg: both firms assigned a 200% mortality rating to the insured), and the LEs are different, the table is the most likely cause of the difference. (NOTE: There are underwriting firms out there touting the use of morality tables that are simply not suitable for use in the life settlement marketplace. Following these so-called “experts” can result in severe consequences). 

    A Comprehensive Perspective 

    If the mortality ratings are not the same between the reports, then we have to look for the other underwriter’s rationale, or some indication as to why they rated the insured the way they did. More often than not, there is no discernible correlation between the morality rating schemes used by various underwriters, and therefore, the differences between two LE reports are driven by significant differences in both the risk assessment methodology and the mortality tables used. When we look for the reason why another underwriter assessed the life differently than we did, we hope to see an indication as to what the other underwriter decided were the primary and secondary impairments, as well as other “comorbidities,” factors that might also be influencing the insured’s degree of impairment.  

    However, what we find most often is a list of health issues using medical jargon, nothing more. Assuming the same medical records were used by us and the other underwriters, we can see where this list comes from, but the list itself tells us nothing about the underwriter’s “view” as to which of these issues is really driving the insured’s mortality rating. As a result, we can always explain why our assessment is what it is, but it is rare that we are able to explain why another underwriter’s view is different. Since it is always the case that we are asked about the difference only when our LE is longer, we assume the other underwriter is never asked by the client why their LE is shorter. (They may be, but we never are). Thus, the client cannot possibly understand the full context of our response, which we always provide. If the client really wants to know why two LEs are different, they have to ask the same question of both underwriters, and they need to be qualified to understand the responses they get. 

    Chris Conway is Chief Development Officer at ISC Services 


    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - October Longevity and Mortality Trends Longevity Risk Volume 2 Issue 10 - October 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Could Climate Change Cause the Buy-In Market To Collapse?

    10 April 2025

    ICS vs Solvency II: Comparing Risk Corrections for Illiquid Liabilities

    10 April 2025

    Falls: Significance in Life Expectancy Underwriting

    13 March 2025

    Spotlight on Longevity Capital Models

    13 March 2025

    Comments are closed.

    Most Popular

    Life Insurer Credit Risk in the News Again but Life Settlement Market Keeps On Keeping On

    10 April 2025

    Capital-Backed Journey Plans Re-Enter Defined Benefit Pension De-Risking Debate as New Rules Loom

    10 April 2025

    Understanding the Impact of Covid-19 on Future Mortality Remains an Almost Impossible Task

    10 April 2025

    Canadian Pension Risk Transfer Market Set To Establish Higher Floor as Aggregate Deal Value Surges

    10 April 2025
    Ad

    Your trusted source for capital markets participation in Life Risk

    X (Twitter) Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Terms and Conditions
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT